Pyrukynd (mitapivat) NDC 71334-205

NDC codes

FDA NDC Directory

Product NDC (as listed)71334-205Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71334-0205Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71334-205-05	71334020505	4 BLISTER PACK in 1 CARTON (71334-205-05) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-205-14)Marketed from Feb 18, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pyrukynd
Generic name (nonproprietary): mitapivat
Active ingredients: Mitapivat — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Agios Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 216196
Marketing start: Feb 18, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2B6 Inducers (Mechanism)Cytochrome P450 2C19 Inducers (Mechanism)Cytochrome P450 2C8 Inducers (Mechanism)Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A Inducers (Mechanism)P-Glycoprotein Inhibitors (Mechanism)Pyruvate Kinase Activators (Mechanism)UGT1A1 Inducers (Mechanism)
Identifiers: Product ID 71334-205_557b465d-234d-75a2-e063-6394a90a070aSPL ID 557b465d-234d-75a2-e063-6394a90a070aSPL set ID 4ccee896-e313-4c6c-9674-b4746ada0a90RxCUI 2594473, 2594479, 2594496, 2594498, 2594501, 2594503, 2594741, 2594742, 2594743, 2594744, 2594745, 2594746, 2594747, 2594748, 2594749, 2594750, 2594794, 2594795UNII 2WTV10SIKH
Pharmacologic class: Pyruvate Kinase Activator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471334020505 followed by a unit qualifier and the quantity

Package 71334-0205-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2026.

Indications (excerpt from the label)

PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 216196

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 216196
Product	Strength	Form · route	Labeler	Product NDC
Pyrukyndmitapivat	Mitapivat 20 mg/1	Tablet, Film coatedOral	Agios Pharmaceuticals, Inc.	71334-210
Pyrukyndmitapivat	—	Kit	Agios Pharmaceuticals, Inc.	71334-225
Pyrukyndmitapivat	Mitapivat 50 mg/1	Tablet, Film coatedOral	Agios Pharmaceuticals, Inc.	71334-215
Pyrukyndmitapivat	Mitapivat 5 mg/1	Tablet, Film coatedOral	Agios Pharmaceuticals, Inc.	71334-220
Pyrukyndmitapivat	—	Kit	Agios Pharmaceuticals, Inc.	71334-230
Aqvesmemitapivat	Mitapivat 100 mg/1	Tablet, Film coatedOral	Agios Pharmaceuticals, Inc.	71334-235